Pharmaceutical

Relief Therapeutics has Published its Annual Report

GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), a biopharmaceutical company committed to…

8 months ago

Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX:…

8 months ago

GE HealthCare Receives FDA Clearance for Portrait VSM, Building on Its Growing Ecosystem of Connected Patient Monitoring Solutions

The portable vital signs monitor (VSM) adds to GE HealthCare’s growing Portrait Ecosystem to help clinicians make timely treatment decisions…

8 months ago

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the…

8 months ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3…

8 months ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a…

8 months ago

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…

8 months ago

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3…

8 months ago

LifeMD Appoints Dr. Calum MacRae to its Board of Directors

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,…

8 months ago